
Opinion|Videos|August 23, 2024
Management of Comment Adverse Effects Associated with mCRPC Therapies
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore strategies for managing common side effects associated with metastatic castration-resistant prostate cancer (mCRPC) treatments, including androgen receptor-targeted therapies.
Advertisement
Episodes in this series

How do you manage common side effects associated with mCRPC treatments, including androgen receptor-targeted therapies?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves first-line Zenflow system for the treatment of BPH
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5

















